Bromocriptine

old drug, new formulation and new indication

R.I.G. Holt, A.H. Barnett, C.J. Bailey

Research output: Contribution to journalArticle

Abstract

Bromocriptine is an ergot alkaloid dopamine D receptor agonist that has been used extensively in the past to treat hyperprolactinaemia, galactorrhoea and Parkinsonism. It is known that hypothalamic hypodopaminergic states and disturbed circadian rhythm are associated with the development of insulin resistance, obesity and diabetes in animals and humans. When administered in the early morning at the start of the light phase, a new quick release (QR) formulation of bromocriptine appears to act centrally to reset circadian rhythms of hypothalamic dopamine and serotonin and improve insulin resistance and other metabolic abnormalities. Phase II and III clinical studies show that QR-bromocriptine lowers glycated haemoglobin by 0.6-1.2% (7-13 mmol/mol) either as monotherapy or in combination with other antidiabetes medications. Apart from nausea, the drug is well tolerated. The doses used to treat diabetes (up to 4.8 mg daily) are much lower than those used to treat Parkinson's disease and have not been associated with retroperitoneal fibrosis or heart valve abnormalities. QR-bromocriptine (Cycloset™) has recently been approved in the USA for the treatment of type 2 diabetes mellitus (T2DM). Thus, a QR formulation of bromocriptine timed for peak delivery in the early morning may provide a novel neurally mediated approach to the control of hyperglycaemia in T2DM.
Original languageEnglish
Pages (from-to)1048-1057
Number of pages10
JournalDiabetes, Obesity and Metabolism
Volume12
Issue number12
Early online date26 Oct 2010
DOIs
Publication statusPublished - Dec 2010

Fingerprint

Drug Compounding
Bromocriptine
Circadian Rhythm
Type 2 Diabetes Mellitus
Insulin Resistance
Ergot Alkaloids
Retroperitoneal Fibrosis
Congenital Heart Defects
Heart Valves
Dopamine Agonists
Glycosylated Hemoglobin A
Parkinsonian Disorders
Hyperglycemia
Nausea
Parkinson Disease
Dopamine
Serotonin
Obesity
Light
Pharmaceutical Preparations

Keywords

  • antidiabetes drug
  • bromocriptine
  • circadian rhythms
  • clinical trials
  • diabetes mellitus
  • drug mechanism
  • glycaemic control
  • treatment

Cite this

Holt, R.I.G. ; Barnett, A.H. ; Bailey, C.J. / Bromocriptine : old drug, new formulation and new indication. In: Diabetes, Obesity and Metabolism. 2010 ; Vol. 12, No. 12. pp. 1048-1057.
@article{b240bdc087464534902f2fdd0e133784,
title = "Bromocriptine: old drug, new formulation and new indication",
abstract = "Bromocriptine is an ergot alkaloid dopamine D receptor agonist that has been used extensively in the past to treat hyperprolactinaemia, galactorrhoea and Parkinsonism. It is known that hypothalamic hypodopaminergic states and disturbed circadian rhythm are associated with the development of insulin resistance, obesity and diabetes in animals and humans. When administered in the early morning at the start of the light phase, a new quick release (QR) formulation of bromocriptine appears to act centrally to reset circadian rhythms of hypothalamic dopamine and serotonin and improve insulin resistance and other metabolic abnormalities. Phase II and III clinical studies show that QR-bromocriptine lowers glycated haemoglobin by 0.6-1.2{\%} (7-13 mmol/mol) either as monotherapy or in combination with other antidiabetes medications. Apart from nausea, the drug is well tolerated. The doses used to treat diabetes (up to 4.8 mg daily) are much lower than those used to treat Parkinson's disease and have not been associated with retroperitoneal fibrosis or heart valve abnormalities. QR-bromocriptine (Cycloset™) has recently been approved in the USA for the treatment of type 2 diabetes mellitus (T2DM). Thus, a QR formulation of bromocriptine timed for peak delivery in the early morning may provide a novel neurally mediated approach to the control of hyperglycaemia in T2DM.",
keywords = "antidiabetes drug, bromocriptine, circadian rhythms, clinical trials, diabetes mellitus, drug mechanism, glycaemic control, treatment",
author = "R.I.G. Holt and A.H. Barnett and C.J. Bailey",
year = "2010",
month = "12",
doi = "10.1111/j.1463-1326.2010.01304.x",
language = "English",
volume = "12",
pages = "1048--1057",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "12",

}

Bromocriptine : old drug, new formulation and new indication. / Holt, R.I.G.; Barnett, A.H.; Bailey, C.J.

In: Diabetes, Obesity and Metabolism, Vol. 12, No. 12, 12.2010, p. 1048-1057.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Bromocriptine

T2 - old drug, new formulation and new indication

AU - Holt, R.I.G.

AU - Barnett, A.H.

AU - Bailey, C.J.

PY - 2010/12

Y1 - 2010/12

N2 - Bromocriptine is an ergot alkaloid dopamine D receptor agonist that has been used extensively in the past to treat hyperprolactinaemia, galactorrhoea and Parkinsonism. It is known that hypothalamic hypodopaminergic states and disturbed circadian rhythm are associated with the development of insulin resistance, obesity and diabetes in animals and humans. When administered in the early morning at the start of the light phase, a new quick release (QR) formulation of bromocriptine appears to act centrally to reset circadian rhythms of hypothalamic dopamine and serotonin and improve insulin resistance and other metabolic abnormalities. Phase II and III clinical studies show that QR-bromocriptine lowers glycated haemoglobin by 0.6-1.2% (7-13 mmol/mol) either as monotherapy or in combination with other antidiabetes medications. Apart from nausea, the drug is well tolerated. The doses used to treat diabetes (up to 4.8 mg daily) are much lower than those used to treat Parkinson's disease and have not been associated with retroperitoneal fibrosis or heart valve abnormalities. QR-bromocriptine (Cycloset™) has recently been approved in the USA for the treatment of type 2 diabetes mellitus (T2DM). Thus, a QR formulation of bromocriptine timed for peak delivery in the early morning may provide a novel neurally mediated approach to the control of hyperglycaemia in T2DM.

AB - Bromocriptine is an ergot alkaloid dopamine D receptor agonist that has been used extensively in the past to treat hyperprolactinaemia, galactorrhoea and Parkinsonism. It is known that hypothalamic hypodopaminergic states and disturbed circadian rhythm are associated with the development of insulin resistance, obesity and diabetes in animals and humans. When administered in the early morning at the start of the light phase, a new quick release (QR) formulation of bromocriptine appears to act centrally to reset circadian rhythms of hypothalamic dopamine and serotonin and improve insulin resistance and other metabolic abnormalities. Phase II and III clinical studies show that QR-bromocriptine lowers glycated haemoglobin by 0.6-1.2% (7-13 mmol/mol) either as monotherapy or in combination with other antidiabetes medications. Apart from nausea, the drug is well tolerated. The doses used to treat diabetes (up to 4.8 mg daily) are much lower than those used to treat Parkinson's disease and have not been associated with retroperitoneal fibrosis or heart valve abnormalities. QR-bromocriptine (Cycloset™) has recently been approved in the USA for the treatment of type 2 diabetes mellitus (T2DM). Thus, a QR formulation of bromocriptine timed for peak delivery in the early morning may provide a novel neurally mediated approach to the control of hyperglycaemia in T2DM.

KW - antidiabetes drug

KW - bromocriptine

KW - circadian rhythms

KW - clinical trials

KW - diabetes mellitus

KW - drug mechanism

KW - glycaemic control

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=77958579813&partnerID=8YFLogxK

U2 - 10.1111/j.1463-1326.2010.01304.x

DO - 10.1111/j.1463-1326.2010.01304.x

M3 - Article

VL - 12

SP - 1048

EP - 1057

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 12

ER -